<DOC>
	<DOC>NCT01476449</DOC>
	<brief_summary>This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.</brief_summary>
	<brief_title>Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema</brief_title>
	<detailed_description>This is a prospective randomized study comparing two groups of patients with diabetic macular edema. One group will receive injections of ranibizumab monthly and the other group will have the option to receive injections of ranibizumab less frequently. That is eligible to receive the injections less frequently will have fewer injections given if the patients in that group are doing well.</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability to provide written informed consent and comply with study assessments for the full duration of the study Age &gt; 18 years Patient related considerations Phakic or pseudophakic patients with a known history of diabetes will be eligible. Women of reproductive age will be required to take a urine pregnancy test prior to administration of the study drug. Disease related considerations: Patients will have met standard, accepted diagnostic criteria for diabetes and will be currently treated with at least one systemic antihyperglycemic or insulin medication. Patients will have a BCVA ETDRS Snellenequivalent less than or equal to 20/40 Central foveal thickness on SDOCT of &gt;300um Pregnancy (positive pregnancy test) or lactation Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated Participation in another simultaneous medical investigation or trial Foveal ischemia on IVFA Intraocular surgery less than 6 months ago Epiretinal membrane of clinical significance Prior vitrectomy Uncontrolled glaucoma Macular or peripheral laser within 90 Days from Day 0 injection Intravitreal steroid injection within 90 days from Day 0 injection Intravitreal or systemic antiVEGF within 30 days from Day 0 injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Diabetic Retinal Swelling</keyword>
	<keyword>DIabetic Eye Disease</keyword>
</DOC>